Clinical trials: Advanced Solid Tumors or Lymphomas
Neoplasms Malignant
A Phase 1 Dose Escalation and Expansion Study of AK117
This is a multicenter, open label, single arm, Phase 1，dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacodynamics, PK, immunogenicity, and preliminary antitumor activity of AK117…
- Trial name
- NCT04728334
- Testing
- AK117
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Akeso
Advanced Solid Tumor, Lymphoma
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
This will be a Phase 1, open-label study of milademetan to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic (PK)/…
- Trial name
- NCT01877382
- Testing
- Milademetan
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumors, Lymphoma
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity [TRA] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and…
- Trial name
- NCT01714947
- Testing
- [^14C]-alisertib, alisertib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors, Lymphoma
Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas
This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.
- Trial name
- NCT00955786
- Testing
- CX-3543
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Cylene Pharmaceuticals
Any Solid Tumor or Lymphoma
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in…
- Trial name
- NCT00698243
- Testing
- OSI-027
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 128 people
- Sponsor
- Astellas Pharma Inc
MTD
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
Primary Objectives Dose escalation phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT06292208
- Testing
- IBD0333
- Where
- China
- Volunteers
- 48 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Advanced Cancer, Lymphoma
Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
The goal of this clinical research study is to find the highest tolerated dose of NC-4016 that can be given to patients with advanced solid tumors or lymphoma. The safety of the drug will also be studied.
- Trial name
- NCT03168035
- Testing
- NC-4016
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- NanoCarrier Co., Ltd.
Solid Tumor, Non-Hodgkin's Lymphoma
A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
This is a multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of ATG-019, a dual inhibitor of PAK4 and NAMPT, alone or…
- Trial name
- TEACH (NCT04281420)
- Testing
- ATG-019, ATG-019 + Niacin ER
- Where
- 8 sites in China, Taiwan
- Volunteers
- 20 people
- Sponsor
- Antengene Therapeutics Limited
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor, Lymphoma
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
This will be a Phase 1, open-label study of DS-8273a to assess its safety and tolerability, identify the Maximum Tolerated Dose and/or Maximum Administered Dose, and assess its properties in subjects with advanced solid tumors or…
- Trial name
- NCT02076451
- Testing
- DS-8273a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Solid Tumors and Lymphomas
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
- Trial name
- NCT03172936
- Testing
- MIW815, PDR001
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
- Trial name
- NCT05607498
- Testing
- EMB07
- Where
- 10 sites in Australia, China
- Volunteers
- 150 people
- Sponsor
- EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Advanced Cancer, Solid Tumor, Adult
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas.
- Conditions
- Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
- Trial name
- NCT03922204
- Testing
- MCLA-145, Pembrolizumab (Keytruda)
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Merus B.V.
Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas
A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
A multicenter, open-label, dose-escalation and dose-expansion phase 1/2 study, to evaluate TY101 safety, tolerability, pharmacokinetic characteristics, effectiveness and immunogenicity in patients with Locally Advanced…
- Trial name
- NCT04458389
- Testing
- TY101
- Where
- 3 sites in China
- Volunteers
- 268 people
- Sponsor
- Tayu Huaxia Biotech Medical Group Co., Ltd.
Neoplasms Malignant
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
This was a first-in-human, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 as monotherapy or in combination with AK104 in subjects…
- Trial name
- NCT04349969
- Testing
- AK117, AK117+AK104
- Where
- 4 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Akesobio Australia Pty Ltd
Solid Tumor, Non Hodgkin Lymphoma
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
- Trial name
- NCT04775680
- Testing
- ADG106 injection, PD-1 antibody injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Adagene (Suzhou) Limited
FL Lymphoma, Epithelioid Sarcoma
Evaluate the Safety and Clinical Activity of HH2853
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II.
- Conditions
- FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
- Trial name
- NCT04390737
- Testing
- HH2853 Tablets
- Where
- 25 sites in United States, China
- Volunteers
- 254 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Solid Tumor, Glioma
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an…
- Conditions
- Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT02273739
- Testing
- Enasidenib
- Where
- 12 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Celgene
Tumors, Lymphoma
A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma
This study will research the side effects of pegaspargase (pronounced "peg-as-par-gase"); its brand name is ONCASPAR® when it is used with another FDA-approved cancer treatment (chemotherapy) drug called gemcitabine HCl…
- Trial name
- NCT00363610
- Testing
- Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Enzon Pharmaceuticals, Inc.